Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Must have received: adjuvant therapy — post-resection

complete disease resection followed by standard-of-care adjuvant treatment

Cannot have received: systemic anticancer therapy

Exception: allowed if >2 weeks or 3 half-lives prior to lymphodepleting chemotherapy; monoclonal antibodies require >3 weeks

Has received systemic anticancer therapy within 2 weeks or 3 half-lives, whichever is shorter, prior to the start of lymphodepleting chemotherapy. For patients treated with monoclonal antibodies, at least 3 weeks must have elapsed prior to the start of lymphodepleting chemotherapy.

Cannot have received: radiation therapy

Exception: allowed if >2 weeks prior to lymphodepleting chemotherapy and recovered from all radiation-related toxicities

Has received prior radiotherapy within 2 weeks of the start of lymphodepleting chemotherapy. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis or colitis.

Cannot have received: genetically modified T or NK cell therapy

Prior genetically modified T or NK cell therapy

Cannot have received: live vaccine

Exception: allowed if >6 weeks prior to TROP2-CAR-NK infusion and not within 24 months post infusion

Has received a live vaccine within 6 weeks prior to TROP2-CAR-NK infusion and for at least 24 months post infusion